GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Intermune, Inc. (ITMN) [hlAlert]

Rating:
Overweight
ITMN
up 286.30 %

Intermune, Inc. (ITMN) rated Overweight with price target $60 by JP Morgan

Posted on: Tuesday,  Apr 13, 2010  8:25 AM ET by JP Morgan

JP Morgan rated Overweight Intermune, Inc. (NASDAQ: ITMN) on 04/13/2010. Previously JP Morgan rated Buy Intermune, Inc. (NASDAQ: ITMN) on 09/27/2007.,
when the stock price was $19.13. Since then, Intermune, Inc. has gained 286.30% as of 09/26/2014's recent price of $73.90.
If you would have followed the previous JP Morgan's recommendation on ITMN, you would have gained 286.3% of your investment in 2556 days.

InterMune Pharmaceuticals Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other disease areas, several of which are in mid-or advanced-stage human testing, known as clinical trials.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/13/2010 8:25 AM Buy
None
48.43 60.00
as of 12/31/2010
1 Week down  -5.29 %
1 Month up  179.37 %
3 Months up  157.63 %
1 YTD up  169.09 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/27/2007 9:25 AM Buy
None
19.13

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy